Earnings Call · Q4 FY2023·2024-02-29

Q4 23EPS +15.79%·Rev n/aQ3 23EPS +2.67%·Rev n/aQ2 23EPS -7.46%·Rev n/aQ1 23EPS -5.00%·Rev n/a⚠ consensus missing

Xenon Pharmaceuticals Inc. XENE

Sherry Aulin — Chief Financial Officer

Ian Mortimer — President and Chief Executive Officer

Chris Kenney — Chief Medical Officer

Chris Von Seggern — Head of Market Research

−0.8%1d on move date−1.7% vs SPY3d−2.5%5d−2.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XENE calls or request research access.

More XENE calls Browse calls Request research access